tbuckley/cabot-search huggingface dataset:
Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord–Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation
Authors: Lei Gao, Yanqi Zhang, Baoyang Hu, Jia Liu, Peiyan Kong, Shifeng Lou, Yi Su, Tonghua Yang, Huimin Li, Yao Liu, Cheng Zhang, Li Gao, Lidan Zhu, Qin Wen, Ping Wang, Xinghua Chen, Jiangfan Zhong, Xi Zhang
Journal: Journal of Clinical Oncology (2016)

Although mesenchymal stromal cells (MSCs) possess immunomodulatory properties and exhibit promising efficacy against chronic graft-versus-host disease (cGVHD), little is known about the efficacy of MSCs in the prophylaxis of cGVHD after HLA-haploidentical hematopoietic stem-cell transplantation (HLA-haplo HSCT).In this multicenter, double-blind, randomized controlled trial, we investigated the incidence and severity of cGVHD among patients, and the changes in T, B, and natural killer (NK) cells after the repeated infusion of MSCs.The 2-year cumulative incidence of cGVHD in the MSCs group was 27.4% (95% CI, 16.2% to 38.6%), compared with 49.0% (95% CI, 36.5% to 61.5%) in the non-MSCs control group (P = .021). Seven patients in the non-MSCs control group had severe lung cGVHD, but no patients in the MSCs group developed typical lung cGVHD (P = .047). After the MSC infusions, increasing memory B lymphocytes and regulatory T cells, as well as the ratio of type 1 T helper to type 2 T helper cells, were observed, whereas the number of NK cells decreased.Our findings suggest that the repeated infusion of MSCs might inhibit cGVHD symptoms in patients after HLA-haplo HSCT, accompanied by changes in the numbers and subtypes of T, B, and NK cells, leading to the acquisition of immune tolerance.
P-094 Early and long-term outcomes of gastric cancer patients treated with perioperative chemotherapy and radical surgery in a single cancer center
Authors: P. Viapiana, W.L. Costa, S. de Castro Ribeiro Heber, H. Jesus Victor, L. Mello Celso, H. Freitas, V. Simonetti, F. Antonio Cury, A. Godoy, I. Farias, L. Diniz Alessandro, J. Fernandez Coimbra Felipe
Journal: Annals of Oncology (2016)
Maternal passive smoking and the risk of developing wheeze in children: how should we deal with it?
Authors: Elida Zairina
Journal: European Respiratory Journal (2016)

Evidence regarding the adverse effects of maternal smoking and tobacco smoke exposure during pregnancy on the fetus has been recognised in a large number studies; however, smoking during pregnancy is still common. Maternal smoking during pregnancy increases the risk of pregnancy complications ( e.g. placental abruption, placenta praevia or premature rupture of the membranes) [1, 2] and poor infant outcomes ( e.g. sudden infant death syndrome, lower respiratory tract illness, restricted fetal growth, pre-term related death, low birth weight infants, asthma or wheeze) [3–7]. Studies have shown that smoking exposure during pregnancy increases the risks of physician-diagnosed asthma and the development of wheeze in childhood [3, 8, 9]. The risks are even higher when the mother shows pre-natal psychological stress [10]. It is known that wheezing may resolve spontaneously during childhood but may persist into adulthood, particularly in young children with severe asthma [11–13], but the question is, can we cut the risk or even prevent it? Cooperation is needed to create smoke-free environments, both private and public, for children and pregnant women <http://ow.ly/hdm5300ExJ5>
The Current State of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care Survey
Authors: Brook A. Calton, Amy Alvarez-Perez, Diane G. Portman, Kavitha J. Ramchandran, Jessica Sugalski, Michael W. Rabow
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: ASCO and IOM recommend palliative care (PC) across health care settings for patients with serious illnesses, including cancer. This study provides an overview of the current availability, structure, and basic quality of PC services within NCCN Member Institutions. Methods: A PC survey was developed by NCCN staff and a working group of PC experts from 11 NCCN Member Institutions under the auspices of the NCCN Best Practices Committee. The survey was piloted and refined by 3 working group members and sent electronically to all 26 NCCN Member Institutions. NCCN staff and working group leaders analyzed the survey data. Results: A total of 22 of 26 institutions responded (85%). All respondents (100%) reported an inpatient PC consult service (staffed by an average of 6.8 full-time equivalents [FTEs], seeing 1,031 consults/year with an average length of stay [LOS] of 10 days). A total of 91% of respondents had clinic-based PC (with an average of 469 consults/year, staffed by an average of 6.8 FTEs, and a 17-day wait time). For clinics, a comanagement care delivery model was more common than strict consultation. Home-based PC (23%) and inpatient PC units (32%) were less prevalent. Notably, 80% of institutions reported insufficient PC capacity compared with demand. Across PC settings, referrals for patients with solid tumors were more common than for hematologic malignancies. Automatic or “triggered” referrals were rare. The most common services provided were symptom management (100%) and advance care planning (96%). Most programs were funded through fee-for-service billing and institutional support. Partnerships with accountable care organizations and bundled payment arrangements were infrequent. PC program data collection and institutional funding for PC research were variable across institutions. Conclusions: Despite the prevalence of PC inpatient and clinic services among participating NCCN Member Institutions, PC demand still exceeds capacity. Opportunities exist for expansion of home-based PC and inpatient PC units, optimizing referrals, research, and payer collaborations.
Frequency and presentation of neuroleptic malignant syndrome: a prospective study
Authors: P E Keck, H G Pope, S L McElroy
Journal: American Journal of Psychiatry (1987)

In an 18-month prospective assessment of 679 hospitalized, neuroleptic-treated patients, the authors, using previously defined operational criteria, diagnosed neuroleptic malignant syndrome in six cases (0.9%). This supports their earlier finding that the syndrome appeared in about 1% of neuroleptic-treated patients.
Field Trial of the Cytoanalyzer: 1,184 Specimens Analyzed&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: W B COURTNEY, A W HILBERG, S C INGRAHAM, R F KAISER, J C PRUITT, M M BOUSER
Journal: JNCI Journal of the National Cancer Institute (1960)

After much research and development the Cytoanalyzer was subjected to its first clinical trial. In this preliminary attempt to prescreen electronically specially prepared uterovaginal specimens, 1,184 specimens were used including 1,163 negatives and 21 from patients with uterine cervical malignancy. The lowest value obtained from any positive smear was established as an arbitrary base-line value of abnormal cells per smear. With this value, 36.6 percent of the smears scanned could have been eliminated as negatives without cytotechnical screening. The results of this trial are encouraging and indicate that automatic electronic prescreening of smears can be an aid to the field of exfoliative cytology.
Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?
Authors: Jeffrey S. Morris, Scott Kopetz
Journal: Clinical Cancer Research (2016)

The tumor microenvironment contributes important information in gene expression signatures but may be susceptible to sampling variance. Mesenchymal signatures in particular may be influenced by sampling of nonrepresentative regions with high stromal content. Appropriate pathology quality control is required to ensure reproducibility of gene expression signatures. Clin Cancer Res; 22(16); 3989-91. ©2016 AACRSee related article by Dunne et al., p. 4095.
198P Molecular biomarker study in randomized phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: XParTS IIb
Authors: A. Tsuburaya, K. Nishikawa, M. Kobayashi, J. Kawada, T. Namikawa, R. Fukushima, H. Kojima, K. Tanabe, K. Yamaguchi, S. Yoshino, M. Takahashi, N. Hirabayashi, S. Sato, H. Nemoto, Y. Rino, T. Yoshikawa, J. Nakajima, P. Tan, S. Morita, J. Sakamoto
Journal: Annals of Oncology (2015)
Prenatal Vitamin D and Offspring Wheezing—Reply
Authors: Augusto A. Litonjua, Scott T. Weiss
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metagenomic Analysis of Sputum Microbiome as a Tool toward Culture-Independent Pathogen Detection of Patients with Ventilator-associated Pneumonia
Authors: Qiulong Yan, Song Cui, Changming Chen, Shenghui Li, Shanshan Sha, Xianyao Wan, Rongli Yang, Yi Xin, Yufang Ma
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges
Authors: George Cholankeril, Ryan B. Perumpail, Edward A. Pham, Aijaz Ahmed, Stephen A. Harrison
Journal: Hepatology (2016)

Cholankeril, George; Perumpail, Ryan B.; Pham, Edward A.; Ahmed, Aijaz; Harrison, Stephen A. Author Information
Cost-comparison analysis of bendamustine, rituximab, etoposide and carboplatin (TREC) vs. RICE/R-DHAP in relapsed lymphoma.
Authors: Anneliese M Bodding-Long, L. Elizabeth Budde, Jennifer E Roden, Ajay K. Gopal, Tara L Chen
Journal: Journal of Clinical Oncology (2015)

e19517 Background: A multicenter phase I study (Budde et al. ASH 2012, final results ASCO 2015) confirmed the safety and efficacy of supplanting ifosfamide with bendamustine within the regimen RICE for relapsed/refractory lymphoma (TREC). TREC is administered in the outpatient setting compared with other salvage strategies which require hospitalization. We hypothesized that TREC would confer cost savings and yield a lower cost per response vs. RICE/R-DHAP. Methods: Medication and non-medication costs (facility, labor, laboratory, etc.) were collected on patients treated with at least one cycle of TREC or RICE/R-DHAP between 7/2010-7/2012. A cost-consequence analysis comparing regimen costs to efficacy results was conducted using a standardized RR of 70%, based on results from the phase I trial and those reported in the literature for RICE/R-DHAP. Results: Baseline demographics were similar between TREC and RICE/R-DHAP groups. The average cost of one cycle of TREC was similar to RICE and R-DHAP. Medication costs were higher with TREC, representing the majority of total regimen cost. Non-medication costs were higher with RICE/R-DHAP, reflecting higher costs associated with facility, labor, and inpatient admissions. The total cost per response was similar between groups; removing drug-related costs, the cost per response of TREC is significantly lower. Conclusions: Although total costs were similar for outpatient TREC compared to inpatient salvage regimens, most of the costs were attributable to the high-cost of bendamustine. Lower medication-related costs and outpatient administration could yield considerable cost savings and lower cost-per-response. TREC (n=7) RICE (n=23) TREC vs. RICE R-DHAP (n=7) TREC vs. R-DHAP Total Cost Average (Range) $19,031 ($15,960- $24,973) $18,340 ($12,774-25,779) p=0.6 $14,023 ($12,091-$15,920) p<0.05 Medication Costs (% of Total Cost) Average $16,385 (86%) $4,964 (27%) $4,584 (33%) Non-Medication Costs (% of Total Cost) Average $2,646 (14%) $13,376 (73%) $9,439 (67%) Cost per Response Total Cost per Response $27,187 $26,200 p=0.3 $20,033 p<0.05 Cost per Response (Non-Medication Related) $3,780 $19,109 p<0.05 $13,485 p<0.05
P-144 Anti –EGRF Monoclonal Antibodies and Surgery of Metastases in the Treatments of Metastatic Colorectal Cancer (mCRC)
Authors: O. Kit, L. Vladimirova, N. Abramova, A. Storozhakova, I. Popova, N. Tikhanovskaya, K. Novoselova
Journal: Annals of Oncology (2016)
Survival and long-term toxicities of biochemotherapy for metastatic melanoma
Authors: D. R. Minor, J. Miller, M. Kashani-Sabet
Journal: Journal of Clinical Oncology (2007)

8553 Purpose: Because long-term survival after therapy for advanced stage IV melanoma is rare, we thought it would be useful to examine our series of survivors treated with biochemotherapy for melanoma to analyze the characteristics of survivors and their chronic toxicities. Patients and Methods: We reviewed our previously reported (J Clin Oncol. 2005:23:16s suppl, abstract 7547) consecutive series of 38 patients treated between 9/02 and 7/04. They received 6 cycles of inpatient temozolomide, cisplatin, vinblastine, decrescendo high- dose iv IL-2 , and interferon followed by maintenance immunotherapy using IL-2 and sargramostim using the O’Day regimen (Clinical Cancer Res. 2002:8:2775).Two of the ten long-term survivors received surgery for resection of residual disease after achieving a partial response with biochemotherapy. Maintenance immunotherapy was given for 6 to 24 months after biochemotherapy. Results: The median progression- free survival was 7.3 months. No patient developed progression later than 17 months after the start of therapy with the progression-free survival curve level at 24%. Median overall survival was 16.2 months. 10 of the 38 patients are alive and disease-free off therapy after an average of 3.3 years follow-up. Durable complete responses were seen in visceral sites including lung, bone, and pericardium, with 8 of 10 long- term survivors having M1B or M1C disease. 3 patients have significant lymphedema related to prior surgery, radiation therapy, or both. 2 patients, one with pre-existing diabetes, have significant persisting neuropathy. 5 of the 10 patients are hypothyroid. Menstrual function returned in the three women under age 45 in this study. Conclusion: This series supports the findings from other series that biochemotherapy, like high-dose IL-2, can give prolonged disease-free survival. Survivors have a high incidence of hypothyroidism but neuropathy and lymphedema, which affected a minority of patients, were the most bothersome long-term toxicities. No significant financial relationships to disclose.
On-line Global/WHO-European Regional Measles Nucleotide Surveillance
Authors: S Gnaneshan, K E Brown, J Green, D  W Brown
Journal: Eurosurveillance (2008)

Measles virus causes an acute infection characterised by rash and fever. Measles infection is preventable by vaccination, but remains a significant cause of childhood mortality in the developing world with an estimated number of approximately 242,000 deaths by measles in 2006 [1].
Reply to Rimbaș et al.
Authors: Hiroshi Kawakami, Kazumichi Kawakubo, Yoshimasa Kubota, Masaki Kuwatani, Naoya Sakamoto
Journal: Endoscopy (2016)

We greatly appreciate the comments of Rimbaș et al. in their letter [1] regarding our recent study that compared the use of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) and endoscopic transpapillary stenting (ETS) in the treatment of malignant distal biliary obstruction [2]. We would like to reply to some of their comments.
A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69.
Authors: Christian Jackisch, Frank Wiebringhaus, Bettina Conrad, Michael Weigel, Bahriye Aktas, Harald Wagner, Kunibert Latos, Andreas Kohls, Ute Bueckner, Tanja Hauzenberger, Nikola Bangemann, John Hackmann, Michael R. Clemens, Bernhard Heinrich, Oliver Tome, Sibylle Loibl, Valentina Nekljudova, Gunter Von Minckwitz
Journal: Journal of Clinical Oncology (2013)

TPS1141 Background: Anthracyclines (A) followed by taxanes (T) are standard of care for neoadjuvant therapy in breast cancer (BC). A reverse sequence of T followed by A was suggested to achieve higher pCR rates. Previous studies have shown that dual anti-HER2 blockade is superior to trastuzumab (H) alone and thus can increase the pCR rate by 20%. Nab-paclitaxel (nP) is a solvent-free formulation of P encapsulated in albumin and might also improve the pCR rate with eventually lower toxicity. Methods: The GeparSepto study (NCT01583426) will randomize 1200 patients to either nP (150 mg/m²) q1w or P (80mg/m²) q1w for 12 weeks followed by 4 cycles conventionally dosed EC (E 90mg/m², C 600 mg/m²) q3w for 4 cycles. Primary objective is to compare the pCR rate (ypT0+ ypN0). Patients with untreated, histologically confirmed cT2- cT4d BC can be included. HER2+ patients receive H (loading dose 8mg/kg; 6 mg/kg) plus pertuzumab (loading dose 840 mg; 420 mg) q3w concomitantly. Biomaterial including FFPE from core biopsy, serum, plasma and full blood is collected. HER2, ER, PgR, Ki67 and SPARC status will be centrally assessed prior to randomization for stratification. P was assumed to achieve a pCR rate of 33% which will be increased to 41% when using nP, corresponding to an odds ratio of 1.41. To investigate resistance to anti-HER2 treatment, patients with HER2+ BC are randomized prior to start of chemotherapy to receive either 6 weeks H, pertuzumab or the combination as biological window with biomaterial collection prior to start of therapy and after week 6 prior to start of chemotherapy. Results: After been approved by ethics committees and authorities recruitment started in 7/2012 in 56 sites. 293 patients were recruited (53 HER2+; 240 HER2-) by 1 st Feb 2013. A first safety interim analysis is planned after 60 patients have finished therapy. Conclusions: GeparSepto investigates the efficacy of neoadjuvant nP compared to solvent-based P given weekly with a dual blockade of the HER2 receptor in HER2-pos BC. Interim safety results for nP will be presented. The window-substudy is funded within the EU-FP7 project RESPONSIFY No 278659. Clinical trial information: NCT01583426.
Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study
Authors: Stephan Stilgenbauer, Florence Cymbalista, Véronique Leblond, Alain Delmer, Stefan Ibach, Sylvain Choquet, Caroline Dartigeas, Bruno Cazin, Olivier Tournilhac, Brigitte Pegourie, Till M Seiler, Martin Sökler, Katja Zirlik, Jürgen Alt, Henriette Huber, Johannes Bloehdorn, Eugen Tausch, Thorsten Zenz, Michael Hallek, Johannes Schetelig, Peter Dreger, Hartmut Döhner
Journal: Blood (2014)
Medicine court: Rogers in practice
Authors: J Veliz, W S James
Journal: American Journal of Psychiatry (1987)

The authors conducted a prospective study of the impact of the Rogers decision involving patients' right to refuse treatment during the first year (1983-1984) of its implementation in the Massachusetts facility for the criminally insane. They learned that of the 98 cases submitted to the probate court, only 39 were heard. The court found that 35 (90%) of the 39 patients whose cases were heard lacked competence to make treatment decisions. Hearings occurred 2-7 months after petitions were signed by treating physicians. In arriving at the decisions the court appeared to rely more on reports of violent incidents than on evidence of mental illness or testimony about competence.
Outbreak of serogroup C meningococcal disease in Veneto region, Italy
Authors: A Ferro, V Baldo, S Cinquetti, P Corziali, G Gallo, G Lustro, P Paludetti, T Menegon, T Baldovin, G Palù, R Trivello
Journal: Eurosurveillance (2008)

Meningococcal infections occur worldwide as endemic disease; there have also been outbreaks in Europe and in the Americas in the last 30 years but they have not reached the high incidence levels of epidemics in other parts of the world [1].
Feasibility and tolerability of self-insertion of a transnasal tube for esophagogastroduodenoscopy: a pilot study
Authors: Pierre Senesse, Geneviève Georges, Sylvie Séville, Nicolas Flori, Anne Stoebner, Eric Assenat, Hélène de Forges
Journal: Endoscopy (2015)

Recently, Quilliot et al. reported, for the first time, that self-insertion of a nasogastric tube may be efficacious and well tolerated in patients receiving enteral nutrition [1]. A similar process was used to increase the tolerability of diagnostic esophagogastroduodenoscopy (EGD) and the confidence of patients undergoing this procedure.
P-016 Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer
Authors: F. Longo Muñoz, J. Earl, J. Martinez Avila, M. Rodriguez Garrote, C. Guerrero, J. Galindo, P. Priego, G. Rodriguez, F. García-Moreno, F. Lopez, A. Hervás, A. Caminoa, I. García, C. Soteras, E. Vázquez-Sequeiros, J. Botella, V. Pachón Olmos, R. Ferreiro Monteagudo, M. Vaz, A. Gómez, C. Guillén-Ponce, A. Carrato
Journal: Annals of Oncology (2016)
Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation
Authors: W Jeffrey Edenfield, Bassam Mattar, Stephen P Anthony, Peter Mutch, Brian Chanas, Mark Smith
Journal: Blood (2015)
Phosphorylation of HeLa Cell Multiprotein DNA Polymerase α Complex: Impact on Activity and Partial Purification of the Associated Kinase
Authors: Jamboor K. Vishwanatha
Journal: Cancer Communications (1989)

Phosphorylation is a major post-translational regulatory mechanism and plays a key role in transduction of mitogenic signals in cell proliferation. The role of phosphorylation and dephosphorylation in regulating the activities of a multiprotein DNA polymerase alpha complex was examined. Treatment of the HeLa cell multiprotein DNA polymerase alpha with calf intestinal alkaline phosphatase resulted in the inactivation of DNA polymerase alpha and DNA primase but had no effect on deoxyribonuclease- and primer-recognition proteins. A protein kinase co-purified with the multiprotein DNA polymerase alpha and was partially purified from HeLa cells. The partially purified kinase was active in phosphorylating dephosphorylated polymerase alpha and used casein and histones as exogenous substrates. This study demonstrates that phosphorylation-dephosphorylation may have modulated the activities of DNA replicative enzymes and suggests a role for specific phosphatases and kinases in this process.
P-098 Prognostic significance of comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: a Single Centre Experience
Authors: P. Aravind, K. Thillai, A. Suddel, J. Karani, D. Lewis, N. Heaton, P. Kane, G. Alkadhimi, D. Sarker, P. Ross
Journal: Annals of Oncology (2016)